GCM
REGN icon

Graham Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Graham Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-712
Closed -$400K – 1541
2025
Q3 		$400K Buy
+712
New +$403K 0.01% 706
2025
Q1 		– Sell
-1,506
Closed -$1.07M – 1479
2024
Q4 		$1.07M Buy
+1,506
New +$1.26M 0.02% 478
2024
Q3 		– Sell
-389
Closed -$409K – 1300
2024
Q2 		$409K Sell
389
-1,149
-75% -$1.11M 0.01% 645
2024
Q1 		$1.48M Sell
1,538
-402
-21% -$382K 0.03% 311
2023
Q4 		$1.7M Buy
+1,940
New +$1.6M 0.04% 245
2023
Q3 		– Sell
-864
Closed -$621K – 1245
2023
Q2 		$621K Buy
+864
New +$666K 0.02% 497
2022
Q3 		– Sell
-3,128
Closed -$1.85M – 1275
2022
Q2 		$1.85M Buy
+3,128
New +$2.03M 0.07% 228

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Graham Capital Management's REGN Position: Q4 2025 in Review

Graham Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 712 shares — an estimated $400K sold.

Graham Capital Management first reported a position in REGN in Q2 2022 and held it in 7 quarters. The position peaked at $1.85M in Q2 2022. 1,385 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

  • Graham Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Graham Capital Management sold 712 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $400K.
  • Graham Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2022 and held it in 7 quarters.
  • Graham Capital Management's Regeneron Pharmaceuticals position peaked at $1.85M in Q2 2022.
  • 1,385 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Graham Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.